Mere months after its cancer blockbuster hopeful topped Bayer’s Stivarga in a phase 3 trial, Exelixis is conducting a ...

A new foundation from the estate of late Microsoft co-founder Paul Allen has launched with a set of four research grant ...

Oral therapy Relyvrio, which Amylyx is again referring to as AMX0035, was tested in progressive supranuclear palsy (PSP), a ...

The personalized orthopedic implant maker restor3d has raised a total of $104 million to boost its commercial plans across ...

Wugen has raised $115 million, tapping a Fidelity-led syndicate to fund its pursuit of FDA approval for the first ...

Philips has begun rolling out a major update to its cardiovascular ultrasound systems, incorporating a host of imaging ...

Nykode Therapeutics has designed a two-year plan to turn its fortunes around. Having lost a deal with Genentech—and with the future of a Regeneron pact uncertain—the Norwegian biotech is focusing on ...

Abbott has collected a green light in Europe for its dissolving, drug-laden stent in peripheral artery disease, following its ...

ProVerum has raised $80 million in venture capital funding to complete the development of its minimally invasive, stentlike implant to relieve the urinary symptoms of an enlarged prostate | The Dublin ...

Novartis is putting down $30 million, with a potential $772 million on the line, to work with BioArctic’s tech to find a new ...

Fosun Pharma has outlicensed a second inflammatory disease candidate to a Western biotech startup right on the heels of a similar deal unveiled earlier this month. | Right on the heels of a similar ...

With the FDA’s go-ahead, Coya plans to launch a multicenter phase 2 trial of COYA 302 in patients with ALS, CEO Arun ...